This article was originally published here
J Med Virol. 2021 May 15. doi: 10.1002/jmv.27076. Online ahead of print.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global health issue which develops a broad range of illness from asymptomatic to fatal respiratory diseases. SARS-CoV-2 infection is associated with oxidative stress that triggers cytokine production, inflammation, and other pathophysiological processes. Glutathione-S-transferase (GST) is an important enzyme that catalyses the conjugation of glutathione (GSH) with electrophiles to protect the cell from oxidative damage and participates in the antioxidant defense mechanism in the lungs. Thus, in this study, we investigated the role of GSTM1 and GSTT1 gene polymorphism with COVID-19 susceptibility, as well as its outcome. The study included 269 RT-PCR confirmed COVID-19 patients with mild (n=149) and severe (n=120) conditions. All subjects were genotyped for GSTM1 and GSTT1 by multiplex polymerase chain reaction (mPCR) followed by statistical analysis. The frequency of GSTM1-/- , GSTT1-/- and GSTM1-/- /GSTT1-/- was higher in severe COVID-19 patients as compared to mild patients but did not observe significant association. In cox hazard model, death was significantly 2.28-fold higher in patients with GSTT1-/- genotype (P = 0.047). In combination, patients having GSTM1+/+ and GSTT1-/- genotypes showed poor survival rate (P = 0.02). Our results suggested that COVID-19 patients with GSTT1-/- genotype showed higher mortality. This article is protected by copyright. All rights reserved.